

Special Issue

Screening, Early Detection and Prevention of Hepato-Pancreato-Biliary (HPB) Cancers

Message from the Guest Editor

Much of the morbidity and mortality caused by human cancer is related to late diagnosis, where surgical and pharmacologic therapies are less effective. Most late-stage pancreatic and liver cancers follow a palliative treatment pathway. Therefore, facilitating early diagnosis is an important strategy to achieve longer survival (WHO, guide to cancer early diagnosis, 2017). In addition, there are measures which can prevent or reduce the chance of HPB cancer in at-risk populations. These measures have highlighted some pharmacological agents, vaccines and supplements that may be recommended for public use. The growing understanding of genomic, epigenomic and machine learning pathways has led to a pronounced diversification of diagnostic options, and thus to a significant improvement in the early diagnosis of cancer. In this Special Issue, innovative screening, early detection and prevention technologies will be highlighted from the perspective of basic, translational and clinical pathway research, with the overall goal of improving them and identifying new potential targets.

Guest Editor

Dr. Zaed Z.R. Hamady

1. Human Development & Health, University of Southampton, Southampton SO16 6YD, UK
2. University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK

Deadline for manuscript submissions

31 January 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/203903

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)